By Fineline Cube 
China-based Jiangsu Sinopep Allsino Biopharmaceutical Co., Ltd. (SHA: 688076) announced a strategic partnership with compatriot firm Vazyme Biotech Co., Ltd (SHA: 688105). The collaboration aims to drive technological advancements and project cooperation in synthetic biology by leveraging their combined expertise in synthetic biology platforms, organic synthesis, and chemical process technologies.
Joint Venture Details
The two companies plan to establish a joint venture (JV) in Nanjing, with Sinopep Allsino holding a 51% stake and Vazyme owning 49%. The JV will be consolidated into Sinopep Allsino’s financial statements. The project will be implemented in two phases. Phase I will focus on facility upgrades and expansions using existing production capacity, including DMF filings for active pharmaceutical ingredients (APIs). Phase II will involve downstream production line construction based on market demand and overall progress. The goal is to establish API and formulation production lines with an annual capacity of approximately 10 tons to meet future market needs.-Fineline Info & Tech